Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation
Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation
Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation
Submitted by
admin
on August 29, 2018 - 10:26am
Source:
CP Wire
News Tags:
Omeros
OMS721
thrombotic microangiopathy
Headline:
Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation
snippet:
OMS721 is also being studied in atypical hemolytic uremic syndrome, IgA nephropathy, and lupus nephritis
The drug also has orphan status for the treatment of primary IgA nephropathy
Do Not Allow Advertisers to Use My Personal information
